NJ MPJE key terms

A drug that federal law requires to be dispensed only on a prescription from a licensed practitioner, marked "Rx only" on its labeling. Dispensing it without a valid order violates the Food, Drug, and Cosmetic Act.

The ten-digit numeric code assigned to each drug product under the Food, Drug, and Cosmetic Act; its three segments identify the labeler, the product, and the package size. Pharmacies use it for ordering, billing, and inventory.

Federal law requiring trading partners to exchange transaction information, transaction history, and a transaction statement with each drug shipment, and to verify and serialize packages so the supply chain can be traced.

A risk management plan the FDA can require for a drug with serious safety concerns; it may include medication guides, restricted distribution, or required testing and registries that a pharmacy must follow before dispensing.

The federal registration issued by the Drug Enforcement Administration that allows a practitioner or pharmacy to handle controlled substances; it must be renewed periodically and kept at the registered location for inspection.

One of five federal categories (I through V) ranking drugs by abuse potential and accepted medical use; the schedule determines ordering, storage, recordkeeping, refill, and prescription requirements that apply.

The order document (paper triplicate or its electronic equivalent, CSOS) that a registrant must use to obtain Schedule I or II substances; each line lists the drug, package size, and quantity, and must be kept as a record.

A complete count of all controlled substances on hand, required at least every two years and at initial registration; Schedule II drugs are counted exactly while Schedules III through V may be estimated if containers are sealed.

The report a registrant files with DEA, ordinarily within one business day of discovery, describing the theft or significant loss of controlled substances and the steps taken to prevent further loss.

A pharmacist's duty to resolve red flags in a controlled substance prescription, such as unusual pattern, distance, or payment method, by verifying with the prescriber and documenting the inquiry before deciding whether to dispense.

The state regulatory body within the Division of Consumer Affairs that licenses pharmacists, registers technicians and interns, permits pharmacies, and adopts and enforces the rules governing pharmacy practice in New Jersey.

The license the New Jersey Board of Pharmacy issues to a specific physical location to operate as a pharmacy; it names the pharmacist-in-charge and must be displayed and kept current.

The pharmacist designated to the Board as the person responsible for a pharmacy's day-to-day compliance with drug, controlled substance, and practice rules at that location.

New Jersey requires pharmacy technicians to be registered with the Board of Pharmacy and to work under pharmacist supervision; permitted duties and any staffing limits are set by Board rule.

The continuing education hours a licensed New Jersey pharmacist must complete and document during each renewal cycle, including any mandated subject areas, as a condition of renewing the license.

A state registration from the New Jersey Division of Consumer Affairs that a practitioner or pharmacy must hold, in addition to a federal DEA registration, before prescribing, dispensing, or storing controlled dangerous substances in the state.

New Jersey's own controlled dangerous substance schedules, which closely track the federal schedules but are established in state statute; a federally scheduled drug is generally controlled in New Jersey as well.

New Jersey requires prescriptions for controlled dangerous substances to be transmitted electronically, subject to defined exceptions and waiver provisions, and pharmacies must be able to receive and process them.

A New Jersey limit on an initial prescription for an opioid to treat acute pain, generally a five-day supply unless the prescriber documents a qualifying reason in the patient record.

The requirement that the pharmacist offer counseling to the patient or caregiver at dispensing on matters such as directions, storage, side effects, and interactions, and document a refusal when counseling is declined.

The items New Jersey and federal rules require on a dispensed prescription label, such as pharmacy identity and address, prescription number, date, patient name, directions, prescriber, drug name and strength, quantity, and refills.

Dispensing a therapeutically equivalent, usually lower-cost product in place of the prescribed brand. New Jersey requires substitution unless the prescriber prohibits it or the patient refuses, with notice to the patient.

An FDA therapeutic equivalence code indicating that two pharmaceutically equivalent products are expected to be bioequivalent; products sharing such a code may generally be interchanged under state substitution law.

Substituting a clinically different drug, often another agent in the same class, under a prescriber-approved protocol or formulary rather than under the automatic generic substitution rules.

The United States Pharmacopeia chapter setting minimum standards for nonsterile compounding, covering personnel training, facility cleaning, equipment, master formulation records, and assignment of beyond-use dates.

The USP chapter governing sterile compounding, including cleanroom and hood classifications, environmental monitoring, garbing, validation of processes, and category-based limits on how long a preparation may be kept.

The USP chapter on handling hazardous drugs, requiring an assessment of risk, containment, engineering controls, personal protective equipment, and documented procedures for receipt, compounding, and disposal.

The date by which a compounded preparation must be used or discarded, calculated from the start of preparation using the applicable USP limits and based on the ingredients, container, and storage conditions.

New Jersey's prescription monitoring database; dispensers report controlled substance dispensing on the required schedule, and authorized prescribers and pharmacists may review a patient's history for clinical and diversion-related decisions.

A pharmacy's written, ongoing system for detecting, documenting, analyzing, and preventing dispensing errors and near misses, required by New Jersey rule and subject to Board review.

Any preventable event that may cause or lead to inappropriate medication use or patient harm, ranging from wrong drug or dose to miscommunication, and which pharmacies must document and review.

The FDA's reporting program for serious adverse events, product problems, and medication errors involving drugs, devices, and biologics, submitted voluntarily or as required by regulation.

New Jersey authority allowing trained, certified pharmacists to administer specified vaccines to patients within defined age ranges, under a protocol or standing order, with documentation and reporting to the state immunization registry.

A written arrangement in which a physician authorizes a pharmacist to initiate, adjust, or monitor drug therapy for a patient under agreed protocols, with documentation and periodic review of the arrangement.

Movement of prescription information between pharmacies so a patient may obtain a refill elsewhere; federal rule permits a Schedule III through V prescription to be transferred only once, and Schedule II cannot be transferred.

FDA categories ranking recall urgency: Class I for reasonable probability of serious harm or death, Class II for temporary or reversible harm, and Class III for violations unlikely to cause harm; pharmacies must act promptly.

A DEA-registered entity that receives expired, unwanted, or recalled controlled substances from pharmacies, arranges for their return or destruction, and documents the transaction for both parties' records.

The cash price a pharmacy charges the general public for a drug, used as a benchmark for third-party reimbursement and subject to state and contract rules on accuracy and disclosure.